XML 48 R33.htm IDEA: XBRL DOCUMENT
v3.26.1

EQUITY (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Equity [Abstract] |
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK | As of December 31, 2025, the Company had outstanding warrants to purchase an aggregate of 26,920,508 shares of common stock, as follows: SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK
|  | Number of underlying Common stock |  |  | Exercise price |  |  | Expiration date
Series G Warrants |  |  | 1,092,344 |  |  | $ | 10.230 |  |  | February 8, 2026
Series J Warrants |  |  | 12,914,086 |  |  | $ | 1.3827 |  |  | -*
Series K Warrants |  |  | 12,914,078 |  |  | $ | 1.3827 |  |  | -*
Total Warrants |  |  | 26,920,508 |  |  |  |  |  |  |
| * | The Series J Warrants and Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 cm and (B) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of CGuard Prime in the U.S. begins. During the years ended December 31, 2025 and 2024, a total of 433,878 and 213,458 warrants expired unexercised, respectively.
SCHEDULE OF STOCK OPTIONS GRANTED | SCHEDULE OF STOCK OPTIONS GRANTED
|  | Year ended December 31 |
|  | 2025 |
|  | Number of options |  |  | Weighted average exercise price |
Outstanding - beginning of the year |  |  | 2,154,143 |  |  |  | 2.76 |
Granted |  |  | 1,119,127 |  |  |  | 2.63 |
Forfeited |  |  | (79,541 | ) |  |  | 3.25 |
Outstanding- end of year |  |  | 3,193,729 |  |  |  | 2.70 |
Exercisable at the end of the year |  |  | 1,612,755 |  |  |  | 2.79 |
INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
| 3) | Stock Options – Non-Employees
|  | The following table summarizes information about stock options granted to non-employees:
|  | Year ended December 31 |
|  | 2025 |
|  | Number of options |  |  | Weighted average exercise price |
Outstanding - beginning of the year |  |  | 916,669 |  |  |  | 2.10 |
Granted |  |  | - |  |  |  | - |
Outstanding - end of year |  |  | 916,669 |  |  |  | 2.10 |
Exercisable at the end of the year |  |  | 639,003 |  |  |  | 2.19 |
| 4) | Restricted Stock – Employees and non-employees
|  | The following table summarizes information about restricted stock granted to employees and non-employees:
|  | Year ended December 31 |
|  | 2025 |
|  |  | Number of restricted stock |
Outstanding - beginning of the year |  |  | 4,073,966 |
Granted |  |  | 3,933,081 |
Forfeited |  |  | (256,170 | )
Vested |  |  | (2,573,691 | )
Outstanding - end of the year |  |  | 5,177,186 |
| 5) | Restricted Stock Units (RSUs) – Employees
|  | The following table summarizes information about RSUs granted to employees:
|  | Year ended December 31 |
|  | 2025 |
|  | Number of RSUs |
Outstanding - beginning of the year |  |  | 1,845,727 |
Granted |  |  | 558,417 |
Outstanding - end of the year |  |  | 2,404,144 |
SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE | SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE
|  |  | Outstanding as of December 31, 2025 |
Exercise price |  |  | Options outstanding |  |  | Weighted average remaining contractual life (years) |  |  | Options exercisable |
$ | 1.15-3.14 |  |  |  | 3,772,718 |  |  |  | 6.98 |  |  |  | 1,926,991 |
$ | 3.30-4.12 |  |  |  | 181,352 |  |  |  | 5.28 |  |  |  | 168,439 |
$ | 4.95-10.05 |  |  |  | 152,275 |  |  |  | 4.27 |  |  |  | 152,275 |
$ | 16.50 |  |  |  | 4,053 |  |  |  | 4.01 |  |  |  | 4,053 |
|  |  |  |  | 4,110,398 |  |  |  | 6.80 |  |  |  | 2,251,758 |
SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES | SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES
|  |  | Year ended December 31 |
|  |  | 2025 |  |  |  | 2024 |
Expected life |  |  | 2; 5.5-6.5 |  |  |  | 5.125-10 years |
Risk-free interest rates |  |  | 3.45% - 3.64%; 3.64%-4.68% |  |  |  | 3.93%-4.44% |
Volatility |  |  | 38.69%- 49.34%; 75.74%-92.69% |  |  |  | 91.82%-119.38% |
Dividend yield |  |  | - |  |  |  | - |
SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE | SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE
|  | Year ended December 31 |
|  | 2025 |  |  | 2024 |
|  | ($ in thousands) |
Cost of revenues |  | $ | 218 |  |  | $ | 256 |
Research and development |  |  | 2,559 |  |  |  | 2,412 |
Sales and marketing |  |  | 1,888 |  |  |  | 1,025 |
General and administrative |  |  | 7,667 |  |  |  | 6,445 |
|  | $ | 12,332 |  |  | $ | 10,138 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration